|Bid||42.31 x 1100|
|Ask||42.39 x 800|
|Day's Range||41.84 - 43.00|
|52 Week Range||36.17 - 58.67|
|Beta (5Y Monthly)||0.06|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||47.62|
All 7 out of 7 eligible patients with relapsed/refractory chronic lymphocytic leukemia (rrCLL), with or without Richter’s Transformation (RT), responded to treatment (Objective Response Rate of 100%)1 GLPG5201 showed no cytokine release syndrome (CRS) higher than grade 2, or immune effector cell-associated neurotoxicity syndrome (ICANS)2 A functionally closed, automated manufacturing platform for cell therapies at the point-of-care will be shown at the Galapagos booth A.103 at the EHA 2023 congr
Key Insights The considerable ownership by retail investors in Galapagos indicates that they collectively have a...
GLPG3667 is an investigational, novel, oral, reversible, and selective tyrosine kinase 2 (TYK2) inhibitor GLPG3667 is currently in development for the treatment of inflammatory and auto-immune diseases and, if approved, has the potential to be the first selective oral TYK2 inhibitor in dermatomyositis Mechelen, Belgium; 23 May 2023, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the first patient was dosed in GALARISSO, the Phase 2 dermatomyositis (DM) trial with GLPG3667
9 poster presentations and 3 abstracts publications reinforce Galapagos' commitment to immunology and the rheumatoid arthritis (RA) patient and healthcare professional communityNew analyses will be presented from long-term extension studies providing insights into filgotinib's effectiveness and safetyInterim baseline characteristics, effectiveness and safety outcomes will be published online from the real-world FILOSOPHY study in RA patients Mechelen, Belgium; 22 May 2023, 22:01 CET; Galapagos N
Every investor on earth makes bad calls sometimes. But really bad investments should be rare. So consider, for a...
Mechelen, Belgium; 5 May 2023, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 1,975,000 subscription rights under new subscription right plans for the benefit of certain members of the personnel of the company and its subsidiaries. On 5 May 2023, the Board of Directors of Galapagos approved “Subscription Right Plan 2023 BE”, intended for members of personnel of the company and its Belgian subsidiary, “Subscription Rig
Progress with immunology and oncology pipeline: First patients dosed in pivotal Phase 3 OLINGUITO study with filgotinib in axial spondyloarthritis (AxSpA)Clinical sites opened to start patient recruitment in Phase 2 GALARISSO study with TYK2 inhibitor product candidate, GLPG3667, in dermatomyositis (DM)On track to report topline results from two CAR-T Phase 1/2 studies in hemato-oncology mid-2023Further expanding CAR-T point-of-care network in Europe, with IND filing in the US expected before ye
Mechelen, Belgium; 2 May 2023, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced the departure of Bart Filius, President, Chief Operating Officer and Chief Financial Officer. Bart Filius joined Galapagos in 2014 as Chief Financial Officer and subsequently took on the responsibility as Chief Operating Officer in 2017. In 2021, he was named President of the company. In his roles, Bart oversaw finance, business development, commercial strategy, human resource
OLINGUITO Phase 3 program in adults with axial spondyloarthritis (AxSpA) to include two parallel studies to investigate the efficacy and safety of filgotinib in patients with active radiographic AxSpA (r-AxSpA) and non-radiographic AxSpA (nr-AxSpA)Results from Phase 2 TORTUGA study showed that filgotinib 200mg was efficacious and well-tolerated in patients with r-AxSpAFilgotinib, an oral, once-daily JAK1 preferential inhibitor, is currently approved in Europe and Japan for the treatment of rheum
Mechelen, Belgium; 25 April 2023, 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announces the approval of all resolutions proposed at its annual shareholders’ meeting (AGM) held today at 14.00 CET. The AGM approved, amongst other items, the re-appointments of Mr. Peter Guenter as non-executive independent director for a period of 4 years, and of Mr. Daniel O’Day and Dr. Linda Higgins as non-executive non-independent directors for a period of 4 years, all effective as of todaythe appoin
Galapagos NV's ( AMS:GLPG ) price-to-sales (or "P/S") ratio of 4.5x might make it look like a strong buy right now...
Galapagos to transfer drug discovery and research activities in Romainville, France to NovAliX, a drug-discovery focused Contract Research Organization (CRO) based in Strasbourg, FranceNovAliX to assume Galapagos’ research capabilities, and Galapagos retains flexibility to access necessary expertise and resources through a five year-collaboration agreementTransaction in the context of Galapagos’ strategic reset announced in 2022; closing expected in July 2023 Mechelen, Belgium and Strasbourg, Fr
Publication of annual report for financial year 2022Annual Shareholders’ Meeting proposed resolutions include re-appointment of Board members and appointment of new statutory auditor Mechelen, Belgium; 23 March 2023, 21.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today publishes its annual report for the financial year 2022 and announces its Annual Shareholders’ Meeting, to be held on Tuesday 25 April 2023, at 2:00 p.m. (CET), at the registered office of the company. T
Mechelen, Belgium; 20 March 2023, 21.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from subscription right exercises. Galapagos issued 61,560 new ordinary shares on 20 March 2023, for a total capital increase (including issuance premium) of EUR 1,769,850.00. In accordance with Belgian transparency legislation1, Galapagos also wishes to note that its total share capital currently amounts to EUR 356,444,938.61, the total number of
Six presentations demonstrate Galapagos’ commitment to the inflammatory bowel disease (IBD) communityNew analyses from Phase 3 SELECTION and SELECTION long-term extension (LTE) studies of Jyseleca® (filgotinib, an oral, once daily, JAK1 preferential inhibitor) will be presentedSELECTIONLTE showed that filgotinib maintained a consistent safety profile; symptomatic remission rates and health-related quality of life (HRQoL) improved in patients with moderate to severe active ulcerative colitis (UC)
Galapagos NV ( AMS:GLPG ) just released its latest full-year report and things are not looking great. It was a pretty...
Key 2022 and post-period events Dr. Paul Stoffelsi appointed as Chief Executive Officer and Chairman of the Board of DirectorsImplemented new strategic direction to accelerate innovation and time-to-patients: Set-up of new innovation model and fit-for-purpose R&D organizationFocus on key therapeutic areas of immunology and oncologyDiscontinuation of activities in fibrosis and kidney diseaseExpansion of drug modalities beyond small molecules, including biologicals and CAR-T Entered into the field
All 7 out of 7 eligible patients with relapsed/refractory Chronic Lymphocytic Leukemia, with or without Richter’s transformation, responded to treatment (Objective Response Rate of 100%)GLPG5201 showed an acceptable safety profile with no cytokine release syndrome (CRS) higher than grade 2, or immune effector cell-associated neurotoxicity syndrome (ICANS) observed Mechelen, Belgium; 9 February 2023, 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today presented encouraging data at the Europea
The two induction cohorts missed the co-primary endpoints of clinical remission and endoscopic response at Week 10In the maintenance phase, filgotinib 200mg once daily achieved the co-primary endpoints of clinical remission and endoscopic response at Week 58The safety findings were generally consistent with the known profile of filgotinib in rheumatoid arthritis (RA) and ulcerative colitis (UC)Galapagos decided not to submit a Marketing Authorization Application in Europe based on these topline
Mechelen, Belgium; 10 January 2023, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from FMR LLC. Pursuant to Belgian transparency legislation1, Galapagos received a transparency notification on 9 January 2023 from FMR LLC, who notified that it holds 3,903,804 of Galapagos’ voting rights, consisting of 3,801,504 ordinary shares and 102,300 equivalent financial instruments. FMR LLC controls investment funds Fidelity Management & Resea
Mechelen, Belgium; 3 January 2023, 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) will participate in the 41th Annual J.P. Morgan Healthcare Conference on January 9-12, 2023. Paul Stoffels1, CEO, will present on Monday, January 9 at 4.30 p.m. PST/7.30 p.m. ET (Tuesday, January 10 at 01.30 a.m. CET). The presentation will be a live audio webcast and can be accessed via the following link. A replay of the webcast will be available on the Galapagos’ website at https://www.glpg.com/webcasts. Abou
Here we present three drug and biotech stocks, VIR, GLPG and PCRX, which took a beating in 2022 but have upside potential for 2023, despite an uncertain macro environment.
Mechelen, Belgium; 22 December 2022, 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced changes in the Executive Committee effective 1 January 2023. Dr. Walid Abi-Saab has decided to retire from the company as Chief Medical Officer and member of the Executive Committee, effective 31 December 2022. He will stay with Galapagos until 31 May 2023 to ensure a smooth transition. The company also announces the retirement of André Hoekema who joined Galapagos in 2005 as Chief Business Off
To get a sense of who is truly in control of Galapagos NV ( AMS:GLPG ), it is important to understand the ownership...
The average of price targets set by Wall Street analysts indicates a potential upside of 34.4% in Galapagos NV (GLPG). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.